Trial intelligence / Profile preview

Anti-osteoporotic Treatments and Cognitive Function in Elderly Osteoporosis

ChiCTR2400090803Phase 4Not yet recruiting

Sponsor: Nanjing Drum-Tower Hospital
Start: Oct 2024
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Countries: 1

Overview

Phase 4 trial of denosumab and teriparatide in osteoporosis (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Cognitive function MMSE score and Change in SF-36 quality of life score from baseline. Planned start Oct 2024; status: not yet recruiting.

Drugs

denosumabteriparatide

Conditions

osteoporosis

Beyond the preview

Go deeper on ChiCTR2400090803.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2400090803.